Melody Harris - Sep 1, 2021 Form 3 Insider Report for SomaLogic, Inc. (SLGC)

Role
President and COO
Signature
/s/ Ruben Gutierrez, Attorney-in-Fact
Stock symbol
SLGC
Transactions as of
Sep 1, 2021
Transactions value $
$0
Form type
3
Date filed
9/10/2021, 07:05 PM
Next filing
Dec 13, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLGC Employee Stock Option (Right to Buy) Sep 1, 2021 Class A Common Stock, par value $0.0001 225K $4.77 Direct F1, F4
holding SLGC Employee Stock Option (Right to Buy) Sep 1, 2021 Class A Common Stock, par value $0.0001 314K $4.77 Direct F1, F4
holding SLGC Employee Stock Option (Right to Buy) Sep 1, 2021 Class A Common Stock, par value $0.0001 210K $4.77 Direct F2, F4
holding SLGC Employee Stock Option (Right to Buy) Sep 1, 2021 Class A Common Stock, par value $0.0001 251K $4.77 Direct F1, F4
holding SLGC Employee Stock Option (Right to Buy) Sep 1, 2021 Class A Common Stock, par value $0.0001 62.9K $4.77 Direct F3, F4
holding SLGC Employee Stock Option (Right to Buy) Sep 1, 2021 Class A Common Stock, par value $0.0001 419K $4.77 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option vest one year after the grant data, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2 Starting 24 months after the grant date, the shares underlying the option vest in 24 equal monthly installments starting on the 1st of following full month.
F3 The shares underlying the option vest in 48 equal monthly installments.
F4 In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock (the "Exchange Ratio"). In addition, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards.